Abstract
OBJECTIVE
Diabetic nephropathy constitutes a major long-term complication in patients with type 1 diabetes mellitus (T1D) and its diagnosis is based on microalbuminuria. The aim of this observational follow-up study was to explore the role of neutrophil-gelatinase-associated lipocalin (NGAL) and cystatin C in unravelling early diabetic nephropathy even in patients with normoalbuminuria.
DESIGN
Fifty-six euthyroid patients with T1D, with mean age 13.1 (SD: 3.2) years, and 49 healthy controls with mean age 12.8 (SD: 6.6) were recruited. Besides standard blood chemistry and urinary albumin excretion, serum NGAL (ELISA) and cystatin C (nephelometry) were measured at enrollment and after 12–15 months. GFR was calculated with the bedside Schwartz formula (eGFR) and the Lund strategy formula (L-eGFR).
RESULTS
At baseline, mean NGAL levels were not significantly different between children with diabetes and controls. At re-evaluation, mean NGAL value and mean eGFR value in patients with diabetes were increased (p = 0.032 and p = 0.003 respectively). At both baseline and reevaluation, NGAL was positively correlated with cystatin C (r=0.41, p<0.001), systolic arterial pressure z-score (r=0.3, p = 0.031) and creatinine (r=0.32, p = 0.010). NGAL correlated negatively with eGFR (r=−0.26, p = 0.049) and L-eGFR (r=−0.33, p = 0.010). Cystatin C had a negative correlation to eGFR (r=−0.29, p = 0.025) and a positive one with creatinine (r=0.35, p = 0.009) at reevaluation. No statistically significant correlation was found between cystatin C and microalbuminuria (p = 0.736).
CONCLUSIONS
NGAL and cystatin C, known markers of renal injury, correlate with renal function decline in T1D, suggesting that they may be used as supplementary tests to urine albumin excretion in order to unmask early renal dysfunction.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nichols GA, Vupputuri S, Lau H, 2011 Medical care costs associated with progression of diabetic nephropathy. Diabetes Care 34: 2374–2378.
Perkins BA, Krolewski AS, 2005 Early nephropathy in type 1 diabetes: a new perspective on who will and who will not progress. Curr Diab Rep 5: 455–463.
Raile K, Galler A, Hofer S, et al, 2007 Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 30: 2523–2528.
Mogensen CE, 1997 How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 46: Suppl 2: 104–111.
Schultz CJ, Konopelska-Bahu T, Dalton RN, et al, 1999 Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 22: 495–502.
Perkins BA, Ficociello LH, Silva KH, et al, 2003 Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348: 2285–2293.
Access O, 2009 Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). BMC Pediatr 9: 79.
Lacquaniti A, Donato V, Pintaudi B, et al, 2013 “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol 50: 935–942.
Hovind P, Rossing P, Tarnow L, et al, 2009 Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 58: 1668–1671.
Perkins BA, Ficociello LH, Roshan B, et al, 2010 In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77: 57–64.
Orchard TJ, Forrest KY, Kuller LH, Becker DJ, 2001 Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 24: 1053–1059.
Caramori ML, Kim Y, Huang C, et al, 2002 Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51: 506–513.
Schultz CJ, Amin R, Dunger DB, 2002 Markers of microvascular complications in insulin dependent diabetes. Arch Dis Child 87: 10–12.
Orchard TJ, 1994 From diagnosis and classification to complications and therapy. DCCT. Part II? Diabetes Control and Complications Trial. Diabetes Care 17: 326–338.
Ellis EN, Warady BA, Wood EG, et al, 1997 Renal structural-functional relationships in early diabetes mellitus. Pediatr Nephrol 11: 584–591.
Drummond KN, Kramer MS, Suissa S, et al, 2003 Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 52: 1818–1824.
Steinke JM, Sinaiko AR, Kramer MS, et al, 2005 The early natural history of nephropathy in type 1 diabetes. Diabetes 54: 2164–2171.
Torbjörnsdotter TB, Perrin NESS, Jaremko GA, Berg UB, 2005 Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes. Pediatr Nephrol 20: 750–758.
Nauta FL, Boertien WE, Bakker SJL, et al, 2011 Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34: 975–981.
Chae H-W, Shin J-I, Kwon A-R, et al, 2012 Spot urine albumin to creatinine ratio and serum cystatin C are effective for detection of diabetic nephropathy in childhood diabetic patients. J Korean Med Sci 27: 784–787.
Thrailkill KM, Moreau CS, Cockrell GE, et al, 2010 Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 37: 336–343.
Schmidt-Ott KM, Mori K, Li JY, et al, 2007 Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18: 407–413.
Devarajan P, 2010 Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med 4: 265–280.
Bagshaw SM, Bennett M, Haase M, et al., 2010 Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 36: 452–461.
Haase-Fielitz A, Haase M, Devarajan P, 2014 Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 51: 335–351.
McKittrick IB, Bogaert Y, Nadeau K, et al, 2011 Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol 301: 1326–1333.
Hawkins R, 2011 New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 31: 72–80.
Dharnidharka VR, Kwon C, Stevens G, 2002 Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40: 221–226.
Finney H, Newman DJ, Thakkar H, et al, 2000 Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child 82: 71–75.
Grubb A, Björk J, Nyman U, et al, 2011 Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest 71: 145–149.
Maahs DM, Ogden LG, Kretowski A, et al, 2007 Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes. Diabetes 56: 2774–2779.
Codoñer-Franch P, Ballester-Asensio E, Martínez-Pons L, et al, 2011 Cystatin C, cardiometabolic risk, and body composition in severely obese children. Pediatr Nephrol 26: 301–307.
Brown SC, O’Reilly PH, 1991 Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 146: 675–679.
Schwartz GJ, Schneider MF, Maier PS, et al, 2012 Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82: 445–453.
Schwartz GJ, Work DF, 2009 Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4: 1832–1843.
Grubb A, 2010 Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check. Scand J Clin Lab Invest 70: 65–70.
Perkins BA, Krolewski AS, 2009 Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 18: 233–240.
Marcun N, 2013 Microalbuminuria in pediatric patients with hypertension. Health 5: 40–46.
Ix JH, Shlipak MG, Chertow GM, Whooley MA, 2007 Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115: 173–179.
Uhlig K, Eckardt K-U, 2012 A decade after the KDOQI CKD guidelines: impact on CKD guidelines. Am J Kidney Dis 60: 705–706.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papadopoulou-Marketou, N., Skevaki, C., Kosteria, I. et al. NGAL and cystatin C: two possible early markers of diabetic nephropathy in young patients with type 1 diabetes mellitus: one year follow up. Hormones 14, 232–240 (2015). https://doi.org/10.14310/horm.2002.1520
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1520